University of Washington-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373